Esperion tanks on warning that the road to an FDA decision could be much, much longer than they thought
Last summer Esperion ($ESPR) triggered a big rally for its shares when CEO Tim Mayleben told investors and analysts that the FDA wouldn’t require a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
